← back to the index
RX-015 biguanide 1978

Phenformin (DBI) — the “Imminent Hazard” Diabetes Pill Banned in 1977, Half Its Victims Dead

iatrogenic-mortalitylactic-acidosismetabolicdiabetologyendocrinologyinternal-medicine1960s1970s
Patients exposed
~385,000 U.S. users in 1977; millions worldwide
Documented harm
~306 documented lactic-acidosis cases at withdrawal; ~50% fatal
On market
1959→1978 (≈19 years)
Status
Withdrawn

Summary

When Joseph Califano, Secretary of Health, Education and Welfare, signed the order suspending phenformin on 25 July 1977, he was invoking a power Congress had granted the Food and Drug Administration fifteen years earlier and which no official had ever used: the declaration that an approved medicine was an "imminent hazard to the public health." Phenformin (phenethylbiguanide), synthesized in 1957 by a team including Seymour Shapiro at the U.S. Vitamin Corporation and marketed in the United States from 1959 by Ciba-Geigy as DBI, had been prescribed to control adult-onset diabetes for nearly two decades. It was withdrawn not because it failed to lower blood sugar — it did that adequately — but because it could quietly poison the body with lactic acid, a complication that killed roughly one of every two patients it reached.

The gap between the promise and the harm was the gap between a surrogate benefit and a survival outcome. Phenformin reliably reduced glycemia, the number physicians could see on a chart; what it did not reliably do was keep patients alive. The biguanide's mechanism — pushing cellular metabolism toward anaerobic glycolysis — produced excess lactate, and in patients with even modest kidney or heart impairment that lactate could accumulate into a metabolic catastrophe. Phenformin-associated lactic acidosis ran at roughly 40 to 64 cases per 100,000 patient-years, and once it occurred it was fatal in approximately half of cases. The drug treated a chronic disease by trading a visible, manageable problem for an occasional, lethal one.

The verdict was therefore plain long before the suspension. As early as 1959 — the same year U.S. marketing began — the literature linked biguanides to lactic acidosis. In 1971 the federally funded University Group Diabetes Program (UGDP) terminated its phenformin arm after finding excess total and cardiovascular mortality, roughly double that of the placebo and insulin groups combined. By October 1976 the FDA's own Endocrinology and Metabolism Advisory Committee had recommended removal. The harm sat in the published record for years while ~385,000 Americans were still taking the drug in 1977.

What forced the cord was not the agency but a consumer group and a lawyer's petition. Ralph Nader's Health Research Group petitioned for suspension on 22 April 1977; Califano acted in July; the drug was off the U.S. market by 15 November 1978. The episode became the founding precedent for emergency drug suspension, the cautionary prologue to its safer sister biguanide metformin, and the textbook case of how a medicine can be effective on the metric it was sold on and still be a net killer.

Timeline

1957
Phenformin synthesized
A team including Seymour Shapiro at the U.S. Vitamin Corporation produces phenethylbiguanide; an American group publishes results for the compound the same year.
1959
U.S. marketing begins; first acidosis signal
Ciba-Geigy markets phenformin as DBI for adult-onset diabetes. In the same period the literature reports an association between biguanides and lactic acidosis.
1961
UGDP launches
The University Group Diabetes Program, a multicenter randomized trial, begins comparing diet, insulin, tolbutamide, and phenformin for vascular outcomes in adult-onset diabetes.
1970
UGDP halts tolbutamide arm
The trial discontinues the sulfonylurea tolbutamide for excess cardiovascular mortality, igniting a decade-long controversy over oral hypoglycemic drugs.
1971
UGDP halts phenformin arm
Phenformin is discontinued after showing total and cardiovascular mortality higher than any other group — roughly double the combined placebo and insulin arms — with no survival benefit over diet alone.
1973
U.S. sales decline
Negative trial data and mounting lactic-acidosis reports erode prescribing.
1976-10
Advisory committee recommends removal
The FDA Endocrinology and Metabolism Advisory Committee recommends phenformin be taken off the market.
1977-04-22
Health Research Group petitions
Ralph Nader's Health Research Group petitions the Secretary of HEW to suspend phenformin as an "imminent hazard to the public health," citing fatal lactic acidosis.
1977-07-25
Califano declares an imminent hazard
HEW Secretary Joseph Califano issues an imminent-hazard suspension — the first-ever use of the FDA's Section 505(e) emergency power — giving physicians roughly 90 days to transition ~385,000 patients to alternatives.
1977-10-25
Forsham v. Califano upholds the order
A federal court (D.D.C.) rejects a physician-led challenge to the suspension, affirming the Secretary's authority; the ruling is sustained on appeal in 1978 (587 F.2d 1128, D.C. Cir.).
1978-11-15
Withdrawal completed
Phenformin is fully removed from the U.S. market. About 306 lactic-acidosis cases have been documented at the time of removal.
1990s-2000s
A foreign afterlife
Phenformin remains legally available in several countries (Italy, Brazil, China, Greece, Portugal, and others); sporadic, often fatal lactic-acidosis cases continue to be reported worldwide.

The Visible Number: How a Surrogate Benefit Sold a Biguanide

Phenformin answered a real clinical demand. By the late 1950s, oral agents that spared diabetics from injections were commercially and medically prized, and phenformin lowered blood glucose without requiring insulin or, at first, much attention to diet. Marketed as DBI from 1959, it joined the sulfonylureas as a pillar of oral diabetes therapy and reached millions of patients across two decades. The selling proposition was a surrogate endpoint: glycemic control, the number visible on a laboratory slip, stood in for the unmeasured outcome that actually mattered — whether the patient lived longer or better. Phenformin moved that visible number reliably, and on that basis it was approved, promoted, and prescribed at scale. The mechanism that produced the benefit, however, carried the seed of the harm. Biguanides suppress hepatic gluconeogenesis and shift peripheral metabolism toward anaerobic glycolysis; the same shift generates lactate. In a healthy patient the load is cleared, but in the diabetic population most likely to take the drug — frequently older, often with subclinical renal or cardiac impairment — clearance can fail, and lactate accumulates. The drug was thus aimed precisely at the patients least able to tolerate its worst effect, and the metric it was sold on never captured that trade-off.

The Signal No One Acted On: UGDP, Lactic Acidosis, and Eighteen Lost Years

The warning did not arrive late; it arrived almost at the beginning and then compounded. A biguanide-acidosis link was in the literature by 1959, the very year U.S. marketing began. The definitive blow came from the government's own trial. The University Group Diabetes Program, launched in 1961 to test whether oral agents reduced vascular complications, instead found in 1971 that the phenformin arm carried total and cardiovascular mortality roughly double that of the combined placebo and insulin groups, with no demonstrated survival advantage over diet. UGDP had already halted its tolbutamide arm in 1970 for similar reasons, and the findings detonated a bitter, years-long dispute in which prominent diabetologists attacked the trial's design rather than accept its result. The controversy bought phenformin time it should not have had. While clinicians argued over methodology, lactic-acidosis case reports accumulated at roughly 40 to 64 per 100,000 patient-years, each carrying a coin-flip chance of death. The FDA's advisory committee recommended removal in October 1976, yet the drug stayed on shelves and in medicine cabinets. As late as 1977, some 385,000 Americans were still taking it. For nearly eighteen years the institutional response to a measured, lethal, mechanistically explained hazard was debate, not withdrawal.

The Reckoning: An Imminent Hazard, a Lawsuit, and a Precedent

Phenformin was pulled not by the regulator's initiative but by external pressure converted into legal force. On 22 April 1977, Ralph Nader's Health Research Group petitioned HEW to suspend the drug as an "imminent hazard to the public health," a statutory category created in 1962 and never once invoked. On 25 July 1977, Secretary Joseph Califano signed the suspension — the first use in FDA history of its emergency power under Section 505(e) of the Federal Food, Drug, and Cosmetic Act — ordering manufacturers to halt distribution and giving physicians roughly ninety days to move patients to insulin, diet, or other agents. The action was immediately contested. In Forsham v. Califano, a group of physicians led by Peter Forsham sued to block the suspension, arguing the data were inconclusive and that no adequate substitute existed for some patients; a federal district court upheld the order on 25 October 1977, and the appellate court affirmed in 1978. Full withdrawal was completed on 15 November 1978. At that point roughly 306 lactic-acidosis cases had been formally documented, a count that the rarity of recognition and reporting almost certainly understated. The reckoning produced no mass-tort billions; its currency was precedent. Phenformin became the case that proved the imminent-hazard mechanism could be wielded, survive judicial review, and clear a market.

Contributing Factors

01
Surrogate-endpoint marketing without a survival mandate
Phenformin was sold on its ability to lower blood glucose — a visible proxy — not on any demonstration that it extended or improved life. Approval and promotion rested on the easy-to-measure benefit while the hard outcome, mortality, went untested until UGDP measured it and found the drug wanting. When the metric that sells a product is not the metric that protects the patient, scale arrives long before truth.
02
A lethal mechanism aimed at the most vulnerable users
The same anaerobic-metabolism shift that lowered glucose generated lactate, and the diabetic population most likely to take the drug — older patients with latent renal or cardiac impairment — was precisely the group least able to clear it. A hazard concentrated in the typical user is not a rare edge case; it is a design flaw in the indication.
03
A clear signal neutralized by methodological dispute
UGDP's 1971 finding of doubled mortality was met not with action but with a decade of expert argument over trial design. The controversy functioned as a delay engine: as long as the result could be framed as contestable, the drug could remain a debate rather than a recall. Disputing the data is something a product can survive commercially in a way that a verdict is not.
04
Regulatory inertia broken only by outside pressure
The FDA had an advisory recommendation to remove phenformin in October 1976 and acted only after a Nader-affiliated consumer group filed a formal petition in April 1977. The agency that approves a drug is structurally reluctant to reverse itself; here the reversal required an external petitioner to force the question and a novel statutory lever to answer it.
05
The unused emergency power as the only adequate remedy
Ordinary withdrawal proceedings were slow; the imminent-hazard authority, dormant since 1962, was the only tool fast enough to halt distribution before the next acidosis death. That the power had never been used in fifteen years shows how rarely regulators reach for emergency suspension — and how much accumulated harm it can take to justify the first time.

Aftermath

The material consequence was immediate and modest in dollar terms: distribution stopped, ~385,000 patients were transitioned to other therapies, and Ciba-Geigy lost a long-standing franchise without the multibillion-dollar litigation that would later define drug recalls. The durable ripple was institutional. Phenformin's suspension established that the FDA's imminent-hazard authority was real, usable, and judicially defensible, a precedent that has shaped emergency drug action ever since. The episode also recast the entire biguanide class. Metformin, phenformin's chemical sibling, generates far less lactate — roughly an order of magnitude fewer acidosis cases per patient-year, with risk largely confined to patients with renal failure — and although it was tarred by association for years and not approved in the United States until 1995, it eventually became the most prescribed oral diabetes drug in the world. The contrast between the two biguanides is now a standard teaching example: same class, same target, vastly different safety, distinguished only by how aggressively each tipped metabolism toward lactate. What remains is a byword. "Phenformin" is invoked whenever an effective, long-marketed drug is found to have carried a rare, lethal, mechanistically predictable harm that the visible efficacy metric concealed — the case that taught regulators an oral medicine can do exactly what it promises and still, on balance, kill.

Lessons

  1. Demand a survival outcome before scaling a surrogate benefit: a drug that reliably moves a number on a chart has proven only that — never let glycemic, lipid, or imaging endpoints stand in for whether patients live longer until a trial has measured that directly.
  2. Map the harm onto the actual user, not the ideal one: when a drug's worst complication concentrates in the very population most likely to take it, treat that overlap as disqualifying, not incidental.
  3. Read a methodological dispute as a clock, not a verdict: if a finding of excess mortality can only be answered by attacking the trial's design, count the patients exposed during every year the argument runs.
  4. Keep the emergency lever sharp and be willing to pull it: a suspension power that sits unused for fifteen years protects no one — build the authority, defend it in court, and accept that the first use will always look drastic.
  5. When the regulator will not move, expect the petitioner to: durable safety often depends on an outside party with standing to force the question, so design independent surveillance and petition rights in from the start rather than waiting for a consumer group to do the agency's work.

References